4. I've also reached out to several other top life sciences VCs, none of whom had heard about Calico before yesterday's announcement. Same goes for some healthcare industry headhunters. In other words, this has legitimately taken folks by surprise.
4. 我也接触了其他几家顶级的生命科学风投公司,没有一家在昨天的声明之前听说过Calico。医疗业的猎头公司也一样。换句话说,他们一直在隐瞒消息,憋着股劲要让人大吃一惊呢。
5. I also contacted a handful of pharma folks, each of whom offered what they admitted to be uninformed speculation. Here was the response I found most interesting (again – smart pharma guy who doesn't know Calico):
5. 我还联系了一些制药行业的从业人员,他们都谈了自己的猜测。下面是我发现的最有趣的的回答(当然,这个聪明的制药公司员工也没听说过Calico)。
"I'd say that Art's background in biotech and gene-driven cancer therapies would mean he'd be likely focusing on identifying the molecular aspects/drivers/signals of cellular aging and looking at interventional therapies targeting those targets. If true, this would be similar to how the oncology field was in the 1980s (wide open, no strategy, no leader, shunned by "real" scientists and most investors)."
“我要说,阿特在生物技术和基因癌症治疗上的背景意味着他可能会专注于研究确定细胞在分子层面/驱动/信号上的老化,寻求针对这些方面的介入疗法。如果真的是这样,与20世纪80年代肿瘤学领域类似的情形(完全开放、不讲策略、没有领袖,“真正”的科学家和大多数投资者都绕着走)将会重现。”
【谷歌的逆天计划 阻止人类衰老】相关文章:
★ 再见北上广!2019年大学生就业报告发布,毕业生正流向二线城市
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15